149 related articles for article (PubMed ID: 26725739)
1. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay.
Yu HB; Zou BY; Wang XL; Li M
Acta Pharmacol Sin; 2016 Jan; 37(1):111-23. PubMed ID: 26725739
[TBL] [Abstract][Full Text] [Related]
2. Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG.
Gillie DJ; Novick SJ; Donovan BT; Payne LA; Townsend C
J Pharmacol Toxicol Methods; 2013; 67(1):33-44. PubMed ID: 23103595
[TBL] [Abstract][Full Text] [Related]
3. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT.
Bridgland-Taylor MH; Hargreaves AC; Easter A; Orme A; Henthorn DC; Ding M; Davis AM; Small BG; Heapy CG; Abi-Gerges N; Persson F; Jacobson I; Sullivan M; Albertson N; Hammond TG; Sullivan E; Valentin JP; Pollard CE
J Pharmacol Toxicol Methods; 2006; 54(2):189-99. PubMed ID: 16563806
[TBL] [Abstract][Full Text] [Related]
4. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.
Bridal TR; Margulis M; Wang X; Donio M; Sorota S
Assay Drug Dev Technol; 2010 Dec; 8(6):755-65. PubMed ID: 20658944
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological analysis of mammalian cells expressing hERG using automated 384-well-patch-clamp.
Haraguchi Y; Ohtsuki A; Oka T; Shimizu T
BMC Pharmacol Toxicol; 2015 Dec; 16():39. PubMed ID: 26671227
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen.
Sorota S; Zhang XS; Margulis M; Tucker K; Priestley T
Assay Drug Dev Technol; 2005 Feb; 3(1):47-57. PubMed ID: 15798395
[TBL] [Abstract][Full Text] [Related]
7. Compilation and physicochemical classification analysis of a diverse hERG inhibition database.
Didziapetris R; Lanevskij K
J Comput Aided Mol Des; 2016 Dec; 30(12):1175-1188. PubMed ID: 27783199
[TBL] [Abstract][Full Text] [Related]
8. Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment.
Brinkwirth N; Takasuna K; Doi M; Becker N; Obergrussberger A; Friis S; Furukawa H; Hasegawa Y; Oka T; Ohtsuki A; Fertig N; Stoelzle-Feix S
J Pharmacol Toxicol Methods; 2020 Sep; 105():106884. PubMed ID: 32565325
[TBL] [Abstract][Full Text] [Related]
9. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-à-go-go related gene potassium channels.
Zou B; Yu H; Babcock JJ; Chanda P; Bader JS; McManus OB; Li M
Assay Drug Dev Technol; 2010 Dec; 8(6):743-54. PubMed ID: 21158688
[TBL] [Abstract][Full Text] [Related]
10. Global analysis reveals families of chemical motifs enriched for HERG inhibitors.
Du F; Babcock JJ; Yu H; Zou B; Li M
PLoS One; 2015; 10(2):e0118324. PubMed ID: 25700001
[TBL] [Abstract][Full Text] [Related]
11. Novel KCNQ2 channel activators discovered using fluorescence-based and automated patch-clamp-based high-throughput screening techniques.
Yue JF; Qiao GH; Liu N; Nan FJ; Gao ZB
Acta Pharmacol Sin; 2016 Jan; 37(1):105-10. PubMed ID: 26725738
[TBL] [Abstract][Full Text] [Related]
12. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a high-throughput fluorescence assay method for HERG potassium channel inhibition.
Dorn A; Hermann F; Ebneth A; Bothmann H; Trube G; Christensen K; Apfel C
J Biomol Screen; 2005 Jun; 10(4):339-47. PubMed ID: 15964935
[TBL] [Abstract][Full Text] [Related]
14. Halide ion effects on human Ether-à-go-go related gene potassium channel properties.
Zeng H; Balasubramanian B; Penniman JR; Kinose F; Salata JJ; Lagrutta A
Assay Drug Dev Technol; 2013; 11(9-10):544-50. PubMed ID: 24147984
[TBL] [Abstract][Full Text] [Related]
15. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
16. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
[TBL] [Abstract][Full Text] [Related]
17. hERG potency estimates based upon dose solution analysis: What have we learned?
Qu Y; Schnier P; Zanon R; Vargas HM
J Pharmacol Toxicol Methods; 2011; 64(3):251-7. PubMed ID: 21888984
[TBL] [Abstract][Full Text] [Related]
18. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
[TBL] [Abstract][Full Text] [Related]
20. A High-Throughput Electrophysiology Assay Identifies Inhibitors of the Inwardly Rectifying Potassium Channel Kir7.1.
Wright PD; Kanumilli S; Tickle D; Cartland J; Bouloc N; Dale T; Tresize DJ; McCloskey C; McCavera S; Blanks AM; Kettleborough C; Jerman JC
J Biomol Screen; 2015 Jul; 20(6):739-47. PubMed ID: 25656238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
